Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2012 2
2013 3
2015 2
2016 2
2017 4
2018 1
2019 3
2020 7
2021 4
2022 4
2023 4
2024 2
2025 4
2026 2

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

39 results

Results by year

Filters applied: . Clear all
Page 1
The immunogenicity and the safety of the adjuvanted glycoprotein E (gE)-based recombinant vaccine against herpes zoster (RZV) in cancer patients during immunotherapy.
Lasagna A, Mele D, Bergami F, Alaimo D, Dauccia C, Alessio N, Comolli G, Pasi F, Muzzi A, Novelli V, Baldanti F, Pedrazzoli P, Cassaniti I. Lasagna A, et al. Among authors: mele d. Hum Vaccin Immunother. 2023 Dec 15;19(3):2288282. doi: 10.1080/21645515.2023.2288282. Epub 2023 Dec 1. Hum Vaccin Immunother. 2023. PMID: 38037900 Free PMC article.
Human Cytomegalovirus Virion-Associated mRNA as a Marker of Productive Infection in Immunocompromised Patients.
Giardina F, Paolucci S, Mele D, Mura O, Ramus M, Sammartino JC, d'Angelo P, Pitrolo AMG, Campanini G, Pattonieri EF, Rampino T, Gregorini M, Compagno F, Briganti DF, Seminari E, Nicola Polverelli, Cassaniti I, Lilleri D, Baldanti F. Giardina F, et al. Among authors: mele d. J Med Virol. 2025 May;97(5):e70378. doi: 10.1002/jmv.70378. J Med Virol. 2025. PMID: 40326958
The 2023 dengue outbreak in Lombardy, Italy: A one-health perspective.
Rovida F, Faccini M, Molina Granè C, Cassaniti I, Senatore S, Rossetti E, Scardina G, Piazza M, Campanini G, Lilleri D, Paolucci S, Ferrari G, Piralla A, Defilippo F, Lelli D, Moreno A, Vezzosi L, Attanasi F, Soresini M, Barozzi M, Cerutti L, Paglia S, Regazzetti A, Marcacci M, Di Donato G, Farioli M, Manica M, Poletti P, Lavazza A, Bonini M, Merler S, Baldanti F, Cereda D; Lombardy Dengue network. Rovida F, et al. Travel Med Infect Dis. 2025 Mar-Apr;64:102795. doi: 10.1016/j.tmaid.2025.102795. Epub 2025 Jan 2. Travel Med Infect Dis. 2025. PMID: 39755224 Free article.
Successful treatment and secondary prophylaxis with pritelivir for a recurrent multidrug-resistant herpes simplex virus 1 infection in an allogeneic haematopoietic stem cell transplant recipient.
Bussini L, Giardina AMF, Paolucci S, Mannina D, Birkmann A, Bartoletti M; Working Group on Infections in ICH. Bussini L, et al. Clin Microbiol Infect. 2025 Jul;31(7):1234-1236. doi: 10.1016/j.cmi.2025.04.011. Epub 2025 Apr 19. Clin Microbiol Infect. 2025. PMID: 40258442 No abstract available.
Ceramide present in cholangiocarcinoma-derived extracellular vesicle induces a pro-inflammatory state in monocytes.
Oliviero B, Dei Cas M, Zulueta A, Maiello R, Villa A, Martinelli C, Del Favero E, Falleni M, Montavoci L, Varchetta S, Mele D, Donadon M, Soldani C, Franceschini B, Maestri M, Piccolo G, Barabino M, Bianchi PP, Banales JM, Mantovani S, Mondelli MU, Caretti A. Oliviero B, et al. Among authors: mele d. Sci Rep. 2023 May 12;13(1):7766. doi: 10.1038/s41598-023-34676-w. Sci Rep. 2023. PMID: 37173330 Free PMC article.
Unique immunological profile in patients with COVID-19.
Varchetta S, Mele D, Oliviero B, Mantovani S, Ludovisi S, Cerino A, Bruno R, Castelli A, Mosconi M, Vecchia M, Roda S, Sachs M, Klersy C, Mondelli MU. Varchetta S, et al. Among authors: mele d. Cell Mol Immunol. 2021 Mar;18(3):604-612. doi: 10.1038/s41423-020-00557-9. Epub 2020 Oct 15. Cell Mol Immunol. 2021. PMID: 33060840 Free PMC article. Clinical Trial.
MICA/B-targeted antibody promotes NK cell-driven tumor immunity in patients with intrahepatic cholangiocarcinoma.
Oliviero B, Varchetta S, Mele D, Pessino G, Maiello R, Falleni M, Tosi D, Donadon M, Soldani C, Franceschini B, Torzilli G, Piccolo G, Barabino M, Opocher E, Maestri M, Bernuzzi S, Wucherpfennig KW, Mondelli MU, Mantovani S. Oliviero B, et al. Among authors: mele d. Oncoimmunology. 2022 Feb 21;11(1):2035919. doi: 10.1080/2162402X.2022.2035919. eCollection 2022. Oncoimmunology. 2022. PMID: 35223192 Free PMC article.
39 results